ArticlePloS one2021
Public investments in the development of GeneXpert molecular diagnostic technology.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Diagnostic Accuracy of Xpert Xpress to SARS-CoV-2: A systematic review.Journal of virological methods · 2022Pooled it
- Performance of the Xpert Xpress Strep A for detection ofMicrobiology spectrum · 2026Article
- Evaluation of fingerstick blood point-of-care testing of hepatitis B DNA for enhanced hepatitis B treatment decision making: a diagnostic accuracy study.Journal of clinical microbiology · 2026Article
- From proposal to compromise: the TRIPS waiver debate and the crisis of WTO decision-making.Globalization and health · 2025Review
- TB vaccine development: monitoring international patent filings to anticipate access challenges.Frontiers in public health · 2025Article
- Strengthening Outbreak Detection in Africa to Achieve the 7-1-7 Global Framework: Challenges and Opportunities.Public health reviews · 2025Review
- Portable microfluidic devices for monitoring antibiotic resistance genes in wastewater.Mikrochimica acta · 2024Review
- Multidrug-resistant tuberculosis treatment outcomes and associated factors at Yirgalem General Hospital, Sidama Region, South Ethiopia: a retrospective cohort study.BMC pulmonary medicine · 2024Article
- Evaluation of the STANDARD M10 MDR-TB and MTB/NTM assays for the detection ofJournal of clinical microbiology · 2024Article
- Rapid Phenotypic and Genotypic Antimicrobial Susceptibility Testing Approaches for Use in the Clinical Laboratory.Antibiotics (Basel, Switzerland) · 2024Review
- The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Review
- Enabling product development partnerships to bring forward the next generation of health technologies.Health affairs scholar · 2024Article
- 'Our project, your problem?' A case study of the WHO's mRNA technology transfer programme in South Africa.PLOS global public health · 2024Article
- Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs.Harm reduction journal · 2023Article
- Diagnostic biomarkers for active tuberculosis: progress and challenges.EMBO molecular medicine · 2022Review
- Authors' Response - A Status Quo of Failure: Time to Fix University Technology Transfer to Address Global Health.Healthcare policy = Politiques de sante · 2022Article
- Towards Accurate Point-of-Care Tests for Tuberculosis in Children.Pathogens (Basel, Switzerland) · 2022Review
- REASSURED Multiplex Diagnostics: A Critical Review and Forecast.Biosensors · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe GeneXpert diagnostic platform from the US based company Cepheid is an automated molecular diagnostic device that performs sample preparation and pathogen detection within a single cartridge-based assay. GeneXpert devices can enable diagnosis at the district level without the need for fully equipped clinical laboratories, are simple to use, and offer rapid results. Due to these characteristics, the platform is now widely used in low- and middle-income countries for diagnosis of diseases such as TB and HIV. Assays for SARS-CoV-2 are also being rolled out. We aimed to quantify public sector investments in the development of the GeneXpert platform and Cepheid's suite of cartridge-based assays.
methodsPublic funding data were collected from the proprietor company's financial filings, grant databases, review of historical literature concerning key laboratories and researchers, and contacting key public sector entities involved in the technology's development. The value of research and development (R&D) tax credits was estimated based on financial filings.
resultsTotal public investments in the development of the GeneXpert technology were estimated to be $252 million, including >$11 million in funding for work in public laboratories leading to the first commercial product, $56 million in grants from the National Institutes of Health, $73 million from other U.S. government departments, $67 million in R&D tax credits, $38 million in funding from non-profit and philanthropic organizations, and $9.6 million in small business 'springboard' grants.
conclusionThe public sector has invested over $250 million in the development of both the underlying technologies and the GeneXpert diagnostic platform and assays, and has made additional investments in rolling out the technology in countries with high burdens of TB. The key role played by the public sector in R&D and roll-out stands in contrast to the lack of public sector ability to secure affordable pricing and maintenance agreements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.